Fig. 4

Efficiency of combined serum EV-SF3B4 and AFP and EV-SF3B4 positivity rates at all HCC stages in the multi-center cohort. A AUCs of the serum EV-SF3B4 and AFP combination for diagnosing HCC in the multi-center cohort. From left to right: diagnoses of all stages of HCC, mUICC stage I or II, and mUICC stage I. B AUCs of the serum EV-SF3B4 and serum AFP combination for diagnosing HCC in a subgroup composed of CH, LC, and HCC in the multi-center cohort. From left to right: diagnoses of all stages of HCC, mUICC stage I or II, and mUICC stage I. C Positive rates of AFP and serum EV-SF3B4 in patients according to liver disease status in the multi-center cohort. D The rate of positive results for serum EV-SF3B4 according to AFP status in patients with HCC, mUICC stage I or II, and mUICC stage I in the multi-center cohort